R--NIBIB Innovation Funnel Commercialization Center IDIQ Contract Ceiling Increase

The National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Department of Health and Human Services, is initiating a non-competitive modification to increase the ceiling of its existing Indefinite-Delivery, Indefinite-Quantity (IDIQ) contract, 75N92022D00013, supporting the NIBIB Innovation Funnel Commercialization Center as part of the Rapid Acceleration of Diagnostics (RADx-Tech) initiative. This modification, solicited under number 75N98026R00128, is authorized under FAR 6.103-1, permitting sole-source award based on the unique capability of the current contractor, VentureWell, to sustain critical commercialization functions for early-stage biomedical technologies. The work involves managing consultants and vendors, conducting risk assessments, maintaining an automated enterprise management system, and aligning innovation efforts across Coordination, Commercialization, and Validation centers to advance prototypes through commercialization pathways. All performance is centered at the NIH headquarters in Bethesda, Maryland. Offerors must submit a capability statement demonstrating total employee count, professional qualifications of technical and medical personnel, facility and equipment descriptions, past project experience, and any other relevant information—without formal page limits or volume requirements. Submission is electronic only, directed to Melanie Suarez and Noelle Decenzo at NIH, by 3:00 p.m. EST on August 5, 2026, with the solicitation number clearly referenced in the subject line. Compliance with SAM.gov registration is mandatory, implicitly requiring a Unique Entity ID and CAGE code, though no socioeconomic set-asides, size certifications, or affirmative disclosures are specified. No formal contract clauses, packaging specifications, inspection criteria, or pricing details are included in the solicitation, reflecting its nature as a non-competitive modification focused on organizational capability rather than competitive trade-offs or detailed technical deliverables. The anticipated modification will be issued around September 2026 to ensure continuous support for NIH’s translational mission.